AN OPEN LETTER TO THE SCIENTIFIC COMMUNITY ON THE POSSIBLE ROLE OF DYSREGULATED BRADYKININ SIGNALING IN COVID-19 RESPIRATORY COMPLICATIONS

Roche, Joseph; Roche, Renuka

doi:10.6084/m9.figshare.12093696.v6

1/1

2 files

AN OPEN LETTER TO THE SCIENTIFIC COMMUNITY ON THE POSSIBLE ROLE OF DYSREGULATED BRADYKININ SIGNALING IN COVID-19 RESPIRATORY COMPLICATIONS

Version 6 2020-04-16, 04:41

Version 5 2020-04-15, 06:07

Version 4 2020-04-13, 15:27

Version 3 2020-04-13, 15:18

Version 2 2020-04-07, 22:01

Version 1 2020-04-07, 20:13

journal contribution

posted on 2020-04-16, 04:41 authored by Joseph RocheJoseph Roche, Renuka Roche

In this Open Letter to the Scientific Community, we propose a model for dysregulated bradykinin signaling in COVID-19 respiratory complications. Based on our model, we suggest the off-label and compassionate use of the FDA-approved bradykinin receptor blocker, icatibant, for patients with unremitting respiratory distress from COVID-19.

Funding

None

History

Usage metrics

Keywords

COVID-19 bradykinin icatibant respiratory distress Pharmacology Pathology Physiology Infectious Agents Infectious Diseases

Licence

CC BY 4.0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

AN OPEN LETTER TO THE SCIENTIFIC COMMUNITY ON THE POSSIBLE ROLE OF DYSREGULATED BRADYKININ SIGNALING IN COVID-19 RESPIRATORY COMPLICATIONS

Funding

None

History

Usage metrics

Categories

Keywords

Licence

Exports